Moroney believes Pfizer's drug pipeline--which includes drugs for asthma, smoking cessation, cancer and osteoporosis--should offset stiff competition from generic-drug makers in aging product lines.

FORBES: Earnings-Safe Stocks

Mensing that failure-to-warn claims against generic drug companies are preempted by federal law, primarily because generic companies have no authority to make unilateral changes to their product labels even if they come to believe that stronger safety warnings are warranted.

FORBES: Connect

According to the 2010 RBC Capital Markets study, when trial victories, settlements between drugmakers and dropped cases are combined, generic companies were able to bring their product to market before the brand-name drug's patent expired in 76 percent of the 371 drug patent suits decided from 2000 through 2009.

NPR: Court: Can Drug Companies Pay To Delay Generics?

The Petitioners asked the Court to review whether federal antitrust laws prohibit the settlement of patent litigation between a branded drug maker and a generic drug company which include a financial incentive for the generic company to hold off marketing its product for a time period.

FORBES: Campaign Against 'Pay-for-Delay' Drug Patent Settlements Suffers Setback at Supreme Court

Value Line forecasts that Teva's growth will slow this year from competition for generic epilepsy drug Gabapentin and multiple sclerosis treatment Copaxone, which is its signal proprietary (that is, nongeneric) product.

FORBES: Drug Test